Scarica l'app Stockscreener
4.46
2.41%
-0.11
Dopo l'orario di chiusura:
4.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.57
Aprire:
$4.6154
Volume 24 ore:
4,805
Relative Volume:
0.27
Capitalizzazione di mercato:
$34.92M
Reddito:
$598.00K
Utile/perdita netta:
$-21.81M
Rapporto P/E:
-1.0825
EPS:
-4.12
Flusso di cassa netto:
$-16.66M
1 W Prestazione:
-0.91%
1M Prestazione:
-3.82%
6M Prestazione:
-20.33%
1 anno Prestazione:
-22.97%
Intervallo 1D:
$4.42
$4.6154
Intervallo di 1 settimana:
$4.30
$4.6154
Portata 52W:
$3.33
$7.13
Pluri Inc Stock (PLUR) Company Profile
Nome
Pluri Inc
Settore
Industria
Telefono
972-74-710-7171
Indirizzo
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Confronta PLUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
4.46 | 35.81M | 598.00K | -21.81M | -16.66M | -4.12 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Pluri Inc Borsa (PLUR) Ultime notizie
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - The Malaysian Reserve
Pluri Inc. reschedules 2025 annual meeting By Investing.com - Investing.com Nigeria
Pluri Inc. reschedules 2025 annual meeting - Investing.com
Pluri (NASDAQ:PLUR) vs. CARGO Therapeutics (NASDAQ:CRGX) Head-To-Head Review - Defense World
Cellular Therapeutics Market Poised for Explosive Growth, Driven by Innovative Companies - citybuzz -
4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market - FinancialContent
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion - TradingView
Pluri Achieves 400% Revenue Surge as Biotech Pioneer Enters $130B Cacao and Coffee Markets - Stock Titan
Pluri (NASDAQ:PLUR) & Qiagen (NYSE:QGEN) Head to Head Contrast - Defense World
Pluri: Fiscal Q3 Earnings Snapshot - New Haven Register
Pluri Regains Nasdaq Compliance Before Deadline - TipRanks
Renaissance Technologies LLC Boosts Stock Position in Pluri Inc. (NASDAQ:PLUR) - Defense World
Q&A with Alejandro Weinstein, Pluri Board of Directors - citybiz
Pluri Inc. sets date for 2025 shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 shareholder meeting - Investing.com
Pluri acquires 71% stake in Kokomodo - Food Business News
Pluri Inc. acquires majority stake in Kokomodo Ltd. By Investing.com - Investing.com Canada
Pluri Acquires 71% Of Kokomodo To Advance Climate-Resilient Cultivated Cacao Production - Nasdaq
Pluri Inc. acquires majority stake in Kokomodo Ltd. - Investing.com
$13.5B Cacao Market Disruption: Pluri Acquires Cellular Agriculture Pioneer Kokomodo for Climate-Resilient Future - Stock Titan
Pluri Inc. enters agreement, issues pre-funded warrants - Investing.com Australia
Pluri Inc. enters agreement, issues pre-funded warrants By Investing.com - Investing.com Canada
Pluristem stock soars to 52-week high, hits $6.63 By Investing.com - Investing.com South Africa
Pluristem stock soars to 52-week high, hits $6.63 - Investing.com Australia
DarioHealth Announces CFO Transition - The Malaysian Reserve
DarioHealth Announces CFO Transition - Benzinga
DarioHealth Taps Israeli CFO Excellence Award Winner to Lead Next Growth Phase - Stock Titan
Pluri Inc. subsidiary loses $4.2 million NIAID contract By Investing.com - Investing.com Canada
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com Australia
Pluri IncPluri Biotech Receives Termination Notice From Niaid Of ContractSEC Filing - marketscreener.com
Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World
Pluri Inc. (NASDAQ:PLUR) Short Interest Update - Defense World
Pluri’s immune cell expansion technologies gain patents - Yahoo Finance
Pluri Announces Expansion of Intellectual Property Portfolio wit - GuruFocus
Pluri secures patents for cancer cell therapy expansion tech By Investing.com - Investing.com South Africa
Pluri Inc. Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - MarketScreener
Pluri secures patents for cancer cell therapy expansion tech - Investing.com India
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - TradingView
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news
Pluri Inc Azioni (PLUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):